Jan Lesniak
YOU?
Author Swipe
View article: Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC Open
Immune checkpoint inhibitors targeting PD-1/PD-L1 are approved for metastatic non-small-cell lung cancer treatment. In clinical practice, the treatment choice depends on visual scoring of PD-L1, which is subjective and semi-quantitative. I…
View article: 605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology Open
Background Exploratory data from single-arm PhI/II clinical trials provide a unique opportunity for predictive biomarker discovery, but have the limitation to estimate the prognostic value in absence of a control arm. This poses a signific…
View article: 583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients Open
Background Immune checkpoint inhibitors (ICIs) targeting PD-1 or its ligand PD-L1 have shown clinical activity in patients with metastatic non-small cell lung cancer (mNSCLC). However, only subgroups of mNSCLC patients respond to ICI, whil…
View article: 365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC)
365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC) Open
Background The pathologist's visual assessment of tumor proportion score (TPS) with 25% cutoff on PD-L1 stained tissue samples is an established method to select metastatic NSCLC patients that are likely to respond to an anti-PD-L1 monothe…